Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MZH8 | ISIN: AU000000ACW3 | Ticker-Symbol: 3AC
Tradegate
25.06.25 | 08:15
0,012 Euro
-4,17 % -0,001
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
ACTINOGEN MEDICAL LIMITED Chart 1 Jahr
5-Tage-Chart
ACTINOGEN MEDICAL LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
0,0110,01313:02
0,0120,01327.06.

Aktuelle News zur ACTINOGEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.02.Actinogen's Xanamem in 2025 - what's happening?2
24.02.Actinogen reports busy 6 months as development of Xanamem molecule ramps up1
13.02.Actinogen Medical - XanaMIA Phase IIb/III study marches on375Actinogen Medical continues to make progress with its 36-week XanaMIA Phase IIb/III study assessing Xanamem in patients with biomarker-positive mild-to-moderate Alzheimer's disease (AD). The company...
► Artikel lesen
12.02.Actinogen Medical Limited: Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal165Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in Alzheimer's disease and major depressive disorder ...
► Artikel lesen
ACTINOGEN Aktie jetzt für 0€ handeln
24.01.Actinogen Medical - executive interview428Actinogen Medical is an ASX-listed Australian biotech developing its lead asset, emestedastat (Xanamem), a specific and selective 11ß-HSD1 inhibitor designed to prevent excess cortisol production in...
► Artikel lesen
16.01.Cambridge Cognition - Expanded partnership with Actinogen1
09.12.24Actinogen Medical Limited: Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial117Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 Appoints US-based Chief Commercial Officer, Andrew Udell Xanamem's...
► Artikel lesen
15.10.24Actinogen Medical - A$11.1m capital raise completed432Actinogen Medical announced the successful completion of its A$3.0m share purchase plan (SPP), which closed 1.3x oversubscribed. With its previously disclosed A$8.1m share placement, total funds from...
► Artikel lesen
07.10.24Actinogen Medical - Funding in place to complete XanaMIA Phase IIb259Actinogen Medical announced a capital increase of up to A$11.1m on 18 September, consisting of the successful completion of an A$8.1m (gross) share placement to existing shareholders and new institutional...
► Artikel lesen
18.09.24XFRA 3AC: WIEDERAUFNAHME/RESUMPTION225FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
16.09.24XFRA 3AC: AUSSETZUNG/SUSPENSION256DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILACTINOGEN MEDICAL...
► Artikel lesen
27.08.24Actinogen Medical - Further positive XanaCIDD results on depression407New data were revealed from Actinogen Medical's ongoing analysis of the now-completed XanaCIDD study that support the view that the company's lead drug candidate, Xanamem, may provide consistent and...
► Artikel lesen
26.08.24Actinogen Medical Limited: Actinogen announces further positive results on depression in the XanCIDD phase 2a trial430Durable benefits previously reported for the MADRS depression scale are supported by the patient-reported outcome of PGI-S and new MADRS responder analyses that underscore benefit at week 10 with a...
► Artikel lesen
22.08.24Actinogen Medical - XanaCIDD data narrow the focus in depression309While the results from Actinogen's XanaCIDD exploratory Phase IIa study in patients with major depressive disorder (MDD) did not meet the primary endpoint in terms of improving cognitive impairment...
► Artikel lesen
12.08.24Actinogen Medical Limited: Actinogen announces achievement of clinically and statistically significant superiority of Xanamem over placebo on depression in XanaCIDD phase 2a trial109There was a clinically meaningful and persistent improvement depression measured by the key secondary endpoint of MADRS.[1] The primary endpoint of superiority to placebo in a cognitive "attention...
► Artikel lesen
12.08.24XFRA 3AC: WIEDERAUFNAHME/RESUMPTION295FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
08.08.24XFRA 3AC: AUSSETZUNG/SUSPENSION276DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILACTINOGEN MEDICAL...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1